Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Safety and Preliminary Efficacy Study of Mesenchymal Precursor Cells (MPCs) in Subjects With Lumbar Back Pain

This study is ongoing, but not recruiting participants.
Sponsor:
Information provided by (Responsible Party):
Mesoblast, Ltd.
ClinicalTrials.gov Identifier:
NCT01290367
First received: February 3, 2011
Last updated: November 6, 2014
Last verified: January 2014

February 3, 2011
November 6, 2014
August 2011
July 2013   (final data collection date for primary outcome measure)
To determine the overall safety of MPCs plus carrier using physical examinations, vital signs, treatment emergent adverse events (TEAEs), and the results of clinical lab tests (hematology, serum chemistry, inflammation, and immunology). [ Time Frame: 3 years ] [ Designated as safety issue: Yes ]
Same as current
Complete list of historical versions of study NCT01290367 on ClinicalTrials.gov Archive Site
  • To evaluate the change of treated lumbar intervertebral discs using Magnetic Resonance Imaging (MRI) at 6 months post injection of MPCs. [ Time Frame: 6 - 36 Months ] [ Designated as safety issue: No ]
  • To evaluate the effectiveness of MPCs in reducing chronic lumbar back pain using the visual analog scale (VAS). [ Time Frame: 1 - 36 Months ] [ Designated as safety issue: No ]
Same as current
Not Provided
Not Provided
 
Safety and Preliminary Efficacy Study of Mesenchymal Precursor Cells (MPCs) in Subjects With Lumbar Back Pain
A Prospective, Double Blind, Controlled Study Evaluating Safety and Preliminary Efficacy of a Single Injection of Adult Mesenchymal Precursor Cells (MPCs) Combined With Hyaluronan in Subjects With Chronic Discogenic Lumbar Back Pain

The purpose of this study is to compare two doses of immunoselected, culture-expanded, nucleated, allogeneic adult MPCs when combined with hyaluronic acid to two control intradiscal injections in subjects with chronic low back pain due to moderate Degenerative Disc Disease (DDD) at one lumbar level from L1 to S1.

All investigational subjects in this study will undergo injection of either 6 million (M) or 18M cells in a hyaluronic acid carrier into the degenerated lumbar disc's nucleus pulposus. All control subjects will undergo an intradiscal control injection with either saline or hyaluronic acid only

This is a prospective, multicenter, double blinded, controlled clinical study comparing two doses of immunoselected, culture-expanded, nucleated, allogeneic adult MPCs when combined with hyaluronic acid to two control intradiscal injections in subjects with chronic low back pain (> 6 months) due to moderate DDD at one lumbar level from L1 to S1 and unresponsive to conservative therapy for at least 3 months (including physical therapy).

After the screening and injection visits, each subject will be evaluated clinically and radiographically at 30 days, and again at 3, 6, 12, 24 and 36 months after injection.

Subjects will be evaluated at the same time points for safety.

Interventional
Phase 2
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Outcomes Assessor)
Primary Purpose: Treatment
Degenerative Disc Disease
  • Biological: Single Dose MPCs Injection
    Injection of Low Dose MPCs with Hyaluronic Acid into the degenerated lumbar disc's nucleus pulposus.
    Other Names:
    • Direct MPCs Lumbar Disc Injection.
    • Stem Cells
  • Procedure: Single injection of saline solution
    Intradiscal control injection with saline solution
    Other Names:
    • Saline injection
    • Sham control
  • Procedure: Single injection of hyaluronic acid
    Intradiscal control injection with hyaluronic acid
    Other Names:
    • Hyaluronic acid injection
    • Vehicle control
  • Biological: Single Dose MPCs Injection
    Injection of HighDose MPCs with Hyaluronic Acid into the degenerated lumbar disc's nucleus pulposus.
    Other Name: Stem Cells
  • Experimental: High Dose MPCs
    Injection of High Dose MPCs with Hyaluronic Acid
    Interventions:
    • Biological: Single Dose MPCs Injection
    • Biological: Single Dose MPCs Injection
  • Experimental: Low Dose MPCs
    Injection of Low Dose MPCs with Hyaluronic Acid
    Interventions:
    • Biological: Single Dose MPCs Injection
    • Biological: Single Dose MPCs Injection
  • Sham Comparator: Saline injection
    Injection of saline solution.
    Intervention: Procedure: Single injection of saline solution
  • Placebo Comparator: Hyaluronic acid injection
    Injection of hyaluronic acid solution
    Intervention: Procedure: Single injection of hyaluronic acid
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Active, not recruiting
100
July 2015
July 2013   (final data collection date for primary outcome measure)

Inclusion Criteria:

  1. Male or females at least 18 years of age.
  2. Have the ability to understand the requirements of the study, to provide written informed consent, and to comply with the study protocol.
  3. Have the ability to understand and provide written authorization for the use and disclosure of personal health information (PHI) [per Health Insurance Portability and Accountability Act (HIPAA) privacy ruling in the US].
  4. Have chronic low back pain for at least 6 months.
  5. Have documented symptomatic diagnosis of DDD of one level from L1-S1 as determined by a change in disc hydration on MRI compared to normal disc with or without an annular fissure or a contained disc herniation.
  6. Have failed 3 months of non-operative low back pain management.
  7. Disc height loss of <30% compared to a normal adjacent disc based upon radiographic evaluation.
  8. Pre-treatment baseline low back pain of at least 40 mm on a 100 mm visual analog scale.
  9. Low back pain greater than leg pain.
  10. Pre-treatment baseline Oswestry Disability Index Questionnaire score of at least 30 on the 100-point questionnaire.

Exclusion Criteria:

  1. Female subjects who are pregnant or nursing, or women planning to become pregnant during the first year (12 months) following surgery.
  2. Have a current or prior history within the last 3 years of neoplasm (excluding basal cell carcinoma) and/or any active neoplasm within the last 24 months, prior to screening.
  3. Patients with compressive pathology due to stenosis or frankly herniated disc or sequestered discs are not candidates.
  4. Intact disc bulge/protrusion or focal herniation at the symptomatic level (s) > 3 mm or presence of disc extrusion or sequestration.
  5. Lumbar spondylitis or other undifferentiated spondyloarthropathy.
  6. Have undergone a previous surgery at the involved levels.
  7. Any lumbar intradiscal injection procedure (e.g., injection of corticosteroids, methylene blue, dextrose, or glucosamine and chondroitin sulfate). Discography may be performed, but must be done at least 2 weeks or more prior to the MPC injection procedure.
  8. Have an acute fracture of the spine at the time of enrollment in the study.
  9. Have a history of epidural steroid injections within 1 week prior to study treatment.
  10. Have a known history of hypersensitivity or anaphylactic reaction to murine or bovine products or dimethyl sulfoxide (DMSO).
  11. Have a positive screen for human immunodeficiency virus (HIV) antibodies.
  12. Have a known history of hypersensitivity or anaphylactic reaction to Hyaluronan.
  13. Have a current or prior history within the last 3 years of neoplasm (excluding basal cell carcinoma) and/or any active neoplasm within the last 24 months, prior to screening.
  14. Have been a recipient of prior stem cell/progenitor cell therapy or other biological intervention to repair the target intervertebral disc.
  15. Are transient or has been treated in the last 6 months before enrollment for alcohol and/or drug abuse in an inpatient substance abuse program.
  16. Currently incarcerated (prisoners).
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United States,   Australia
 
NCT01290367
MSB-DR001
Yes
Mesoblast, Ltd.
Mesoblast, Ltd.
Not Provided
Study Director: Roger Brown Mesoblast, Ltd.
Mesoblast, Ltd.
January 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP